Omega Fund Management, LLC reported 10 holdings worth US$186M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Omega Fund Management, LLC reported 10 holdings worth US$186M as of Jun 30, 2026. Largest: Bicara Therapeutics Inc., Nuvation Bio Inc. and Kestra Medical Technologies, Ltd. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 10
- Value as reported
- US$186M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Bicara Therapeutics Inc. | 1.82M | US$54.1M | 29.1% |
| Nuvation Bio Inc. | 8.08M | US$45.9M | 24.7% |
| Kestra Medical Technologies, Ltd. | 1.02M | US$26M | 14.0% |
| Bridgebio Oncology Therapeutics, Inc. | 3.29M | US$25.1M | 13.5% |
| Beta Bionics, Inc. | 1.32M | US$20.6M | 11.1% |
| Alumis Inc. | 241K | US$6.79M | 3.7% |
| Sana Biotechnology, Inc. | 844K | US$2.94M | 1.6% |
| Imagenebio, Inc. | 455K | US$2.69M | 1.4% |
| Engene Holdings Inc. | 876K | US$1.52M | 0.82% |
| Odyssey Therapeutics, Inc. | 2,893 | US$54,128 | 0.03% |
| Replimune Group, Inc. | 0 | US$0 | 0.00% |